A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg;   Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg;   Drug: Umeclidinium 62.5 mcg;   Device: Placebo ELLIPTA inahler;   Drug: Albuterol/Salbutamol
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified April 2016

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *